TD Cowen Reaffirms Buy Rating for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating reiterated by stock analysts at TD Cowen in a research note issued to investors on Friday,Benzinga reports. They currently have a $115.00 price objective on the healthcare product maker’s stock. TD Cowen’s price target indicates a potential upside of 14.19% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the company. Raymond James Financial cut their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday. Robert W. Baird started coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Finally, Leerink Partners cut their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Abbott Laboratories Trading Up 1.9%

ABT stock opened at $100.71 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company’s 50-day simple moving average is $89.89 and its 200 day simple moving average is $102.17. The company has a market capitalization of $175.41 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the firm posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Activity

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of ABT. Brighton Jones LLC raised its position in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank lifted its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the period. Main Street Financial Solutions LLC grew its position in shares of Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its holdings in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after acquiring an additional 292,547 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.